

# John K Hsiao

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8842817/john-k-hsiao-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58  
papers

12,152  
citations

37  
h-index

59  
g-index

59  
ext. papers

13,349  
ext. citations

8  
avg, IF

5.13  
L-index

#	Paper	IF	Citations
58	Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1209-23	59.2	4423
57	Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. <i>Schizophrenia Research</i> , <b>2005</b> , 80, 19-32	3.6	885
56	Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 1525-38	59.2	875
55	Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. <i>Archives of General Psychiatry</i> , <b>2007</b> , 64, 633-47		781
54	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 600-610	11.9	682
53	Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 600-10	11.9	359
52	Barriers to employment for people with schizophrenia. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 411-7	11.9	327
51	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 611-622	11.9	283
50	Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. <i>American Journal of Psychiatry</i> , <b>2008</b> , 165, 844-54	11.9	230
49	Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. <i>Schizophrenia Research</i> , <b>2008</b> , 101, 273-86	3.6	222
48	Diagnosing diagnoses. Receiver operating characteristic methods and psychiatry. <i>Archives of General Psychiatry</i> , <b>1989</b> , 46, 664-7		219
47	Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 2080-9	11.9	218
46	Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 428-36	11.9	212
45	Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. <i>American Journal of Psychiatry</i> , <b>2011</b> , 168, 831-9	11.9	180
44	Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. <i>Schizophrenia Research</i> , <b>2008</b> , 105, 175-87	3.6	179
43	Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 611-22	11.9	153
42	The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls. <i>Neuropsychopharmacology</i> , <b>1993</b> , 9, 277-91	8.7	151

41	Quantitative examination of tissue concentration profiles associated with microdialysis. <i>Journal of Neurochemistry</i> , <b>1992</b> , 58, 931-40	6	134
40	Quantitative microdialysis: analysis of transients and application to pharmacokinetics in brain. <i>Journal of Neurochemistry</i> , <b>1991</b> , 57, 103-19	6	129
39	Effects of different semipermeable membranes on in vitro and in vivo performance of microdialysis probes. <i>Journal of Neurochemistry</i> , <b>1990</b> , 54, 1449-52	6	121
38	Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 415-27	11.9	117
37	Results of phase 3 of the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , <b>2009</b> , 107, 1-12	3.6	106
36	National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology. <i>American Journal of Geriatric Psychiatry</i> , <b>2001</b> , 9, 346-360	6.5	103
35	What CATIE found: results from the schizophrenia trial. <i>Psychiatric Services</i> , <b>2008</b> , 59, 500-6	3.3	89
34	Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. <i>Biological Psychiatry</i> , <b>2009</b> , 66, 1013-22	7.9	81
33	Measuring outcome priorities and preferences in people with schizophrenia. <i>British Journal of Psychiatry</i> , <b>2005</b> , 187, 529-36	5.4	68
32	In vivo evidence that lithium inactivates Gi modulation of adenylate cyclase in brain. <i>Journal of Neurochemistry</i> , <b>1992</b> , 59, 200-5	6	67
31	Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. <i>American Journal of Psychiatry</i> , <b>2009</b> , 166, 583-90	11.9	65
30	Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. <i>Schizophrenia Research</i> , <b>2008</b> , 103, 104-9	3.6	59
29	The effects of intravenous clomipramine on neurohormones in normal subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1989</b> , 68, 632-7	5.6	55
28	Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 449-59	1.3	52
27	Monoamine neurotransmitter interactions and the prediction of antidepressant response. <i>Archives of General Psychiatry</i> , <b>1987</b> , 44, 1078-83		52
26	The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. <i>Schizophrenia Research</i> , <b>2008</b> , 100, 39-52	3.6	45
25	Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. <i>Archives of General Psychiatry</i> , <b>2007</b> , 64, 1259-68		45
24	Abnormal neuroendocrine responsivity to acute i.v. clomipramine challenge in depressed patients. <i>Psychiatry Research</i> , <b>1990</b> , 31, 39-47	9.9	41

23	Lithium effects on noradrenergic-linked adenylate cyclase activity in intact rat brain: an in vivo microdialysis study. <i>Brain Research</i> , <b>1991</b> , 538, 333-6	3.7	37
22	The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5-hydroxyindoleacetic acid ratio. <i>Clinical Pharmacology and Therapeutics</i> , <b>1987</b> , 42, 547-54	6.1	37
21	Intravenous alprazolam challenge in normal subjects. Biochemical, cardiovascular, and behavioral effects. <i>Psychopharmacology</i> , <b>1989</b> , 99, 508-14	4.7	31
20	Quantitative microdialysis. <i>Handbook of Behavioral Neuroscience</i> , <b>1991</b> , 7, 47-80		30
19	In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis. <i>Experimental Neurology</i> , <b>1990</b> , 110, 187-93	5.7	26
18	Lithium administration modulates platelet Gi in humans. <i>Life Sciences</i> , <b>1992</b> , 50, 227-33	6.8	25
17	A study of the TRH test in a family with psychiatric illness: a reflection on the TRH test as a state-trait marker. <i>Biological Psychiatry</i> , <b>1985</b> , 20, 570-2	7.9	22
16	Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2007</b> , 7, 103-11	2.2	20
15	Methodology of microdialysis of neostriatum in hemiparkinsonian nonhuman primates. <i>Experimental Neurology</i> , <b>1990</b> , 110, 181-6	5.7	20
14	Clinical investigation of monoamine neurotransmitter interactions. <i>Psychopharmacology</i> , <b>1993</b> , 112, S76-84	4.7	19
13	Interpreting the results of the CATIE study. <i>Psychiatric Services</i> , <b>2006</b> , 57, 139	3.3	15
12	Is there paradoxical growth hormone response to thyrotropin-releasing hormone in depression?. <i>Biological Psychiatry</i> , <b>1986</b> , 21, 595-600	7.9	15
11	ECT and Neurological Disorders. <i>Convulsive Therapy</i> , <b>1987</b> , 3, 121-136		13
10	Dose-dependent effects of intravenous alprazolam on neuroendocrine, biochemical, cardiovascular, and behavioral parameters in humans. <i>Psychopharmacology</i> , <b>1993</b> , 111, 295-300	4.7	9
9	Cost-effectiveness of schizophrenia pharmacotherapy. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 678; author reply 678-9	11.9	6
8	A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensemble and on multivariate algorithms, to characterize late onset Alzheimer's disease. <i>Scientific Reports</i> , <b>2020</b> , 10, 12063	4.9	5
7	Nonlinear Z-score modeling for improved detection of cognitive abnormality. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2019</b> , 11, 797-808	5.2	5
6	Medication-free Intervals and Schizophrenia Research Editors' Introduction. <i>Schizophrenia Bulletin</i> , <b>1997</b> , 23, 1-1	1.3	3

5	ECT treatment does not enhance neuroendocrine responses to serotonergic challenge. <i>Journal of Psychopharmacology</i> , <b>1992</b> , 6, 501-8	4.6	2
4	Cardiovascular response to speaking in schizophrenics. <i>Psychiatry Research</i> , <b>1987</b> , 22, 69-79	9.9	2
3	Regional brain metabolism as predictors of clozapine response. <i>Clinical Neuropharmacology</i> , <b>1992</b> , 15 Suppl 1 Pt A, 399A-400A	1.4	1
2	Activation in young rats induced by LY134046, an inhibitor of phenylethanolamine N-methyltransferase. <i>Psychopharmacology</i> , <b>1989</b> , 98, 240-4	4.7	1
1	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>Focus (American Psychiatric Publishing)</i> , <b>2006</b> , 4, 539-552	1.1	